Advent Pharma (ADVENT) 주식 개요제약 회사인 어드벤트 파마는 방글라데시에서 동물 건강 관리 의약품, 영양 보충제, 가축용 사료 첨가제를 제조, 수입, 판매하는 회사입니다. 자세히 보기ADVENT 펀더멘털 분석스노우플레이크 점수가치 평가1/6미래 성장0/6과거 실적2/6재무 건전성6/6배당1/6위험 분석지난 5년간 매년 수익이 14.5% 감소했습니다.의미 있는 수익이 없습니다(BDT458M)의미 있는 시가총액이 없습니다(BDT1B)모든 위험 점검 보기ADVENT Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value৳Current Price৳14.1041.0% 고평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture0606m2016201920222025202620282031Revenue ৳456.6mEarnings ৳47.9mAdvancedSet Fair ValueView all narrativesAdvent Pharma Ltd. 경쟁사Silco PharmaceuticalsSymbol: DSE:SILCOPHLMarket cap: ৳1.7bTechno DrugsSymbol: DSE:TECHNODRUGMarket cap: ৳5.8bOrion InfusionSymbol: DSE:ORIONINFUMarket cap: ৳6.3bNavana PharmaceuticalsSymbol: DSE:NAVANAPHARMarket cap: ৳7.1b가격 이력 및 성과Advent Pharma 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가৳14.1052주 최고가৳17.2052주 최저가৳11.50베타0.301개월 변동1.44%3개월 변동0.71%1년 변동5.22%3년 변동-46.39%5년 변동-33.72%IPO 이후 변동-60.45%최근 뉴스 및 업데이트Board Change • 9hLess than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. 2 independent directors (7 non-independent directors). Independent Director A.K.M. Hussain was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공시 • Apr 29Advent Pharma Ltd. to Report Q3, 2026 Results on Apr 30, 2026Advent Pharma Ltd. announced that they will report Q3, 2026 results on Apr 30, 2026공시 • Jan 26Advent Pharma Ltd. to Report Q2, 2026 Results on Jan 29, 2026Advent Pharma Ltd. announced that they will report Q2, 2026 results on Jan 29, 2026공시 • Nov 10Advent Pharma Ltd. to Report Q1, 2026 Results on Nov 13, 2025Advent Pharma Ltd. announced that they will report Q1, 2026 results on Nov 13, 2025공시 • Oct 28Advent Pharma Ltd. announces Annual dividend, payable on February 01, 2026Advent Pharma Ltd. announced Annual dividend of BDT 0.0500 per share payable on February 01, 2026, ex-date on November 23, 2025 and record date on November 20, 2025.공시 • Oct 27Advent Pharma Ltd., Annual General Meeting, Dec 31, 2025Advent Pharma Ltd., Annual General Meeting, Dec 31, 2025, at 12:00 Central Asia Standard Time. Location: hybrid system, Bangladesh더 많은 업데이트 보기Recent updatesBoard Change • 9hLess than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. 2 independent directors (7 non-independent directors). Independent Director A.K.M. Hussain was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공시 • Apr 29Advent Pharma Ltd. to Report Q3, 2026 Results on Apr 30, 2026Advent Pharma Ltd. announced that they will report Q3, 2026 results on Apr 30, 2026공시 • Jan 26Advent Pharma Ltd. to Report Q2, 2026 Results on Jan 29, 2026Advent Pharma Ltd. announced that they will report Q2, 2026 results on Jan 29, 2026공시 • Nov 10Advent Pharma Ltd. to Report Q1, 2026 Results on Nov 13, 2025Advent Pharma Ltd. announced that they will report Q1, 2026 results on Nov 13, 2025공시 • Oct 28Advent Pharma Ltd. announces Annual dividend, payable on February 01, 2026Advent Pharma Ltd. announced Annual dividend of BDT 0.0500 per share payable on February 01, 2026, ex-date on November 23, 2025 and record date on November 20, 2025.공시 • Oct 27Advent Pharma Ltd., Annual General Meeting, Dec 31, 2025Advent Pharma Ltd., Annual General Meeting, Dec 31, 2025, at 12:00 Central Asia Standard Time. Location: hybrid system, Bangladesh공시 • Oct 20Advent Pharma Ltd. to Report Fiscal Year 2025 Results on Oct 26, 2025Advent Pharma Ltd. announced that they will report fiscal year 2025 results on Oct 26, 2025공시 • Apr 28Advent Pharma Ltd. to Report Q3, 2025 Results on Apr 30, 2025Advent Pharma Ltd. announced that they will report Q3, 2025 results on Apr 30, 2025공시 • Jan 27Advent Pharma Ltd. to Report Q2, 2025 Results on Jan 30, 2025Advent Pharma Ltd. announced that they will report Q2, 2025 results on Jan 30, 2025Reported Earnings • Nov 15Full year 2024 earnings released: EPS: ৳0.90 (vs ৳1.06 in FY 2023)Full year 2024 results: EPS: ৳0.90 (down from ৳1.06 in FY 2023). Revenue: ৳571.7m (up 2.4% from FY 2023). Net income: ৳84.0m (down 15% from FY 2023). Profit margin: 15% (down from 18% in FY 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 9% per year whereas the company’s share price has fallen by 13% per year.Upcoming Dividend • Nov 14Upcoming dividend of ৳0.10 per shareEligible shareholders must have bought the stock before 21 November 2024. Payment date: 22 December 2024. Payout ratio is a comfortable 20% but the company is paying out more than the cash it is generating. Trailing yield: 1.2%. Lower than top quartile of Bangladeshi dividend payers (4.5%). Lower than average of industry peers (3.6%).공시 • Nov 11Advent Pharma Ltd. to Report Q1, 2025 Results on Nov 13, 2024Advent Pharma Ltd. announced that they will report Q1, 2025 results on Nov 13, 2024New Risk • Nov 06New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. Cash payout ratio: 138% Dividend yield: 1.1% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 12% per year over the past 5 years. Minor Risks Dividend is not well covered by cash flows (138% cash payout ratio). Revenue is less than US$5m (৳569m revenue, or US$4.7m). Market cap is less than US$100m (৳1.65b market cap, or US$13.8m).Declared Dividend • Oct 31Dividend of ৳0.10 announcedShareholders will receive a dividend of ৳0.10. Ex-date: 21st November 2024 Payment date: 22nd December 2024 Dividend yield will be 0.6%, which is lower than the industry average of 2.5%. Sustainability & Growth Dividend is covered by earnings (20% earnings payout ratio) but not covered by cash flows (138% cash payout ratio). The dividend has increased by an average of 5.2% per year over the past 6 years and payments have been stable during that time. The company's earnings per share (EPS) would need to decline by 78% to shift the payout ratio to a potentially unsustainable range, which is more than the 12% EPS decline seen over the last 5 years.공시 • Oct 30Advent Pharma Ltd., Annual General Meeting, Dec 29, 2024Advent Pharma Ltd., Annual General Meeting, Dec 29, 2024, at 12:00 Central Asia Standard Time.Valuation Update With 7 Day Price Move • Oct 23Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ৳19.80, the stock trades at a trailing P/E ratio of 20x. Average trailing P/E is 19x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 31% over the past three years.공시 • Oct 21Advent Pharma Ltd. to Report Fiscal Year 2024 Results on Oct 28, 2024Advent Pharma Ltd. announced that they will report fiscal year 2024 results on Oct 28, 2024Valuation Update With 7 Day Price Move • Sep 26Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ৳19.90, the stock trades at a trailing P/E ratio of 20.1x. Average trailing P/E is 21x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 23% over the past three years.Buy Or Sell Opportunity • Sep 26Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 23% to ৳19.90. The fair value is estimated to be ৳25.32, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.1% over the last 3 years. Earnings per share has declined by 5.5%.공시 • Sep 03Advent Pharma Ltd. Appoints Md. Delwar Hossen as Company SecretaryAdvent Pharma Ltd. announced that as per the decision of the Board of Directors, Mr. Md. Delwar Hossen has been appointed as the Company Secretary of the company.Buy Or Sell Opportunity • Jun 13Now 20% overvaluedOver the last 90 days, the stock has fallen 11% to ৳25.40. The fair value is estimated to be ৳21.14, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.1% over the last 3 years. Earnings per share has declined by 5.5%.New Risk • May 10New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: ৳564m (US$4.8m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.2% average weekly change). Earnings have declined by 12% per year over the past 5 years. Minor Risks Revenue is less than US$5m (৳564m revenue, or US$4.8m). Market cap is less than US$100m (৳2.81b market cap, or US$24.0m).Valuation Update With 7 Day Price Move • May 02Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ৳26.90, the stock trades at a trailing P/E ratio of 27.3x. Average trailing P/E is 26x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 48% over the past three years.공시 • Apr 30Advent Pharma Ltd. to Report Q3, 2024 Results on Apr 29, 2024Advent Pharma Ltd. announced that they will report Q3, 2024 results on Apr 29, 2024Reported Earnings • Feb 09Second quarter 2024 earnings released: EPS: ৳0.27 (vs ৳0.28 in 2Q 2023)Second quarter 2024 results: EPS: ৳0.27 (down from ৳0.28 in 2Q 2023). Revenue: ৳137.1m (up 4.1% from 2Q 2023). Net income: ৳25.1m (down 5.5% from 2Q 2023). Profit margin: 18% (down from 20% in 2Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Feb 05Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ৳28.60, the stock trades at a trailing P/E ratio of 28.6x. Average trailing P/E is 26x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 31% over the past three years.공시 • Jan 24Advent Pharma Ltd. to Report Q2, 2023 Results on Jan 30, 2024Advent Pharma Ltd. announced that they will report Q2, 2023 results on Jan 30, 2024New Risk • Jan 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Bangladeshi stocks, typically moving 5.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 11% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (5.6% average weekly change). Market cap is less than US$100m (৳2.29b market cap, or US$20.9m).Valuation Update With 7 Day Price Move • Dec 10Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ৳27.00, the stock trades at a trailing P/E ratio of 25.5x. Average trailing P/E is 28x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 24% over the past three years.Upcoming Dividend • Nov 14Upcoming dividend of ৳0.20 per share at 0.9% yieldEligible shareholders must have bought the stock before 21 November 2023. Payment date: 28 January 2024. Payout ratio is a comfortable 19% but the company is not cash flow positive. Trailing yield: 0.9%. Lower than top quartile of Bangladeshi dividend payers (3.3%). Lower than average of industry peers (2.5%).공시 • Nov 13Advent Pharma Ltd. to Report Q1, 2024 Results on Nov 14, 2023Advent Pharma Ltd. announced that they will report Q1, 2024 results on Nov 14, 2023공시 • Oct 31+ 1 more updateAdvent Pharma Ltd., Annual General Meeting, Dec 28, 2023Advent Pharma Ltd., Annual General Meeting, Dec 28, 2023, at 12:00 Bangladesh Standard Time.공시 • Oct 20Advent Pharma Ltd. to Report Fiscal Year 2023 Results on Oct 28, 2023Advent Pharma Ltd. announced that they will report fiscal year 2023 results on Oct 28, 2023Reported Earnings • May 18Third quarter 2023 earnings released: EPS: ৳0.28 (vs ৳0.29 in 3Q 2022)Third quarter 2023 results: EPS: ৳0.28 (down from ৳0.29 in 3Q 2022). Revenue: ৳149.4m (up 3.0% from 3Q 2022). Net income: ৳26.5m (down 3.4% from 3Q 2022). Profit margin: 18% (down from 19% in 3Q 2022). The decrease in margin was driven by higher expenses.Reported Earnings • Feb 15Second quarter 2023 earnings released: EPS: ৳0.28 (vs ৳0.28 in 2Q 2022)Second quarter 2023 results: EPS: ৳0.28 (up from ৳0.28 in 2Q 2022). Revenue: ৳131.7m (up 4.4% from 2Q 2022). Net income: ৳26.6m (up 2.2% from 2Q 2022). Profit margin: 20% (in line with 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.Valuation Update With 7 Day Price Move • Dec 21Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to ৳23.30, the stock trades at a trailing P/E ratio of 19.7x. Average trailing P/E is 28x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 21% over the past three years.Valuation Update With 7 Day Price Move • Dec 04Investor sentiment improved over the past weekAfter last week's 19% share price gain to ৳28.40, the stock trades at a trailing P/E ratio of 24x. Average trailing P/E is 24x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 41% over the past three years.Reported Earnings • Nov 27Third quarter 2022 earnings released: EPS: ৳0.29 (vs ৳0.22 in 3Q 2021)Third quarter 2022 results: EPS: ৳0.29 (up from ৳0.22 in 3Q 2021). Revenue: ৳145.1m (up 15% from 3Q 2021). Net income: ৳27.5m (up 32% from 3Q 2021). Profit margin: 19% (up from 17% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 8 experienced directors. No highly experienced directors. 2 independent directors (7 non-independent directors). Independent Director Sheikh Karimuzzaman was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공시 • Nov 01Advent Pharma Ltd. Recommends Cash Dividend for the Year Ended June 30, 2022The Board of Directors of Advent Pharma Ltd. has recommended 2% cash dividend only for general shareholders (Excluding Sponsors and Directors) for the year ended June 30, 2022.Valuation Update With 7 Day Price Move • Oct 19Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to ৳24.50, the stock trades at a trailing P/E ratio of 20.7x. Average trailing P/E is 24x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 26% over the past three years.Valuation Update With 7 Day Price Move • Aug 31Investor sentiment improved over the past weekAfter last week's 19% share price gain to ৳28.40, the stock trades at a trailing P/E ratio of 24x. Average trailing P/E is 25x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 11% over the past three years.Reported Earnings • May 29Third quarter 2022 earnings released: EPS: ৳0.29 (vs ৳0.22 in 3Q 2021)Third quarter 2022 results: EPS: ৳0.29 (up from ৳0.22 in 3Q 2021). Revenue: ৳145.1m (up 15% from 3Q 2021). Net income: ৳27.5m (up 32% from 3Q 2021). Profit margin: 19% (up from 17% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has remained flat, which means it is well ahead of earnings.Board Change • Apr 27Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 8 experienced directors. No highly experienced directors. 2 independent directors (7 non-independent directors). Independent Director Sheikh Karimuzzaman was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Mar 14Investor sentiment improved over the past weekAfter last week's 15% share price gain to ৳28.60, the stock trades at a trailing P/E ratio of 25.7x. Average trailing P/E is 26x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 9.3% over the past three years.Upcoming Dividend • Nov 14Upcoming dividend of ৳0.20 per shareEligible shareholders must have bought the stock before 21 November 2021. Payment date: 16 January 2022. Trailing yield: 0.8%. Lower than top quartile of Bangladeshi dividend payers (3.0%). Lower than average of industry peers (1.7%).Valuation Update With 7 Day Price Move • Oct 20Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ৳28.80, the stock trades at a trailing P/E ratio of 27.8x. Average trailing P/E is 28x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 3.2% over the past three years.Valuation Update With 7 Day Price Move • Oct 05Investor sentiment improved over the past weekAfter last week's 23% share price gain to ৳32.20, the stock trades at a trailing P/E ratio of 31.1x. Average trailing P/E is 29x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 31% over the past three years.Reported Earnings • Sep 10Third quarter 2021 earnings released: EPS ৳0.23 (vs ৳0.23 in 3Q 2020)The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2021 results: Revenue: ৳125.2m (down 14% from 3Q 2020). Net income: ৳20.8m (up 1.4% from 3Q 2020). Profit margin: 17% (up from 14% in 3Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Jun 08Investor sentiment improved over the past weekAfter last week's 20% share price gain to ৳26.30, the stock trades at a trailing P/E ratio of 25.5x. Average trailing P/E is 22x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 2.9% over the past three years.Valuation Update With 7 Day Price Move • May 17Investor sentiment improved over the past weekAfter last week's 16% share price gain to ৳23.10, the stock trades at a trailing P/E ratio of 22.4x. Average trailing P/E is 20x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 23% over the past three years.Is New 90 Day High Low • Jan 07New 90-day high: ৳23.70The company is up 14% from its price of ৳20.73 on 08 October 2020. The Bangladeshi market is up 13% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 20% over the same period.Reported Earnings • Dec 24Third quarter 2020 earnings released: EPS ৳0.23The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2020 results: Revenue: ৳144.8m (down 9.2% from 3Q 2019). Net income: ৳20.5m (down 54% from 3Q 2019). Profit margin: 14% (down from 28% in 3Q 2019). The decrease in margin was primarily driven by lower revenue.공시 • Jul 07Advent Pharma Ltd. to Report Q3, 2020 Results on Jun 24, 2020Advent Pharma Ltd. announced that they will report Q3, 2020 results on Jun 24, 2020주주 수익률ADVENTBD PharmaceuticalsBD 시장7D7.6%-0.6%-0.3%1Y5.2%4.6%4.6%전체 주주 수익률 보기수익률 대 산업: ADVENT은 지난 1년 동안 4.6%의 수익을 기록한 BD Pharmaceuticals 산업과 동일한 성과를 보였습니다.수익률 대 시장: ADVENT은 지난 1년 동안 4.6%의 수익을 기록한 BD 시장과 동일한 성과를 보였습니다.주가 변동성Is ADVENT's price volatile compared to industry and market?ADVENT volatilityADVENT Average Weekly Movement4.2%Pharmaceuticals Industry Average Movement4.7%Market Average Movement5.3%10% most volatile stocks in BD Market7.6%10% least volatile stocks in BD Market3.2%안정적인 주가: ADVENT는 지난 3개월 동안 BD 시장에 비해 주가 변동성이 크지 않았습니다.시간에 따른 변동성: ADVENT의 주간 변동성(4%)은 지난 1년 동안 안정적이었습니다.회사 소개설립직원 수CEO웹사이트2007317Faria Alamwww.adventpharmabd.com제약 회사인 어드벤트 파마는 방글라데시에서 동물 건강 관리 의약품, 영양 보충제, 가축용 사료 첨가제를 제조, 수입, 판매하는 회사입니다. 이 회사는 가금류, 양식 및 가축 제품을 제공합니다. 분말, 볼러스, 액상 제형의 제품을 제공합니다.더 보기Advent Pharma Ltd. 기초 지표 요약Advent Pharma의 순이익과 매출은 시가총액과 어떻게 비교됩니까?ADVENT 기초 통계시가총액৳1.31b순이익 (TTM)৳48.03m매출 (TTM)৳458.15m27.3x주가수익비율(P/E)2.9x주가매출비율(P/S)ADVENT는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표ADVENT 손익계산서 (TTM)매출৳458.15m매출원가৳319.10m총이익৳139.05m기타 비용৳91.02m순이익৳48.03m최근 보고된 실적Mar 31, 2026다음 실적 발표일해당 없음주당순이익(EPS)0.52총이익률30.35%순이익률10.48%부채/자본 비율4.9%ADVENT의 장기 실적은 어땠습니까?과거 실적 및 비교 보기배당0.4%현재 배당 수익률7%배당 성향View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/20 02:07종가2026/05/20 00:00수익2026/03/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Advent Pharma Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Board Change • 9hLess than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. 2 independent directors (7 non-independent directors). Independent Director A.K.M. Hussain was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공시 • Apr 29Advent Pharma Ltd. to Report Q3, 2026 Results on Apr 30, 2026Advent Pharma Ltd. announced that they will report Q3, 2026 results on Apr 30, 2026
공시 • Jan 26Advent Pharma Ltd. to Report Q2, 2026 Results on Jan 29, 2026Advent Pharma Ltd. announced that they will report Q2, 2026 results on Jan 29, 2026
공시 • Nov 10Advent Pharma Ltd. to Report Q1, 2026 Results on Nov 13, 2025Advent Pharma Ltd. announced that they will report Q1, 2026 results on Nov 13, 2025
공시 • Oct 28Advent Pharma Ltd. announces Annual dividend, payable on February 01, 2026Advent Pharma Ltd. announced Annual dividend of BDT 0.0500 per share payable on February 01, 2026, ex-date on November 23, 2025 and record date on November 20, 2025.
공시 • Oct 27Advent Pharma Ltd., Annual General Meeting, Dec 31, 2025Advent Pharma Ltd., Annual General Meeting, Dec 31, 2025, at 12:00 Central Asia Standard Time. Location: hybrid system, Bangladesh
Board Change • 9hLess than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. 2 independent directors (7 non-independent directors). Independent Director A.K.M. Hussain was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공시 • Apr 29Advent Pharma Ltd. to Report Q3, 2026 Results on Apr 30, 2026Advent Pharma Ltd. announced that they will report Q3, 2026 results on Apr 30, 2026
공시 • Jan 26Advent Pharma Ltd. to Report Q2, 2026 Results on Jan 29, 2026Advent Pharma Ltd. announced that they will report Q2, 2026 results on Jan 29, 2026
공시 • Nov 10Advent Pharma Ltd. to Report Q1, 2026 Results on Nov 13, 2025Advent Pharma Ltd. announced that they will report Q1, 2026 results on Nov 13, 2025
공시 • Oct 28Advent Pharma Ltd. announces Annual dividend, payable on February 01, 2026Advent Pharma Ltd. announced Annual dividend of BDT 0.0500 per share payable on February 01, 2026, ex-date on November 23, 2025 and record date on November 20, 2025.
공시 • Oct 27Advent Pharma Ltd., Annual General Meeting, Dec 31, 2025Advent Pharma Ltd., Annual General Meeting, Dec 31, 2025, at 12:00 Central Asia Standard Time. Location: hybrid system, Bangladesh
공시 • Oct 20Advent Pharma Ltd. to Report Fiscal Year 2025 Results on Oct 26, 2025Advent Pharma Ltd. announced that they will report fiscal year 2025 results on Oct 26, 2025
공시 • Apr 28Advent Pharma Ltd. to Report Q3, 2025 Results on Apr 30, 2025Advent Pharma Ltd. announced that they will report Q3, 2025 results on Apr 30, 2025
공시 • Jan 27Advent Pharma Ltd. to Report Q2, 2025 Results on Jan 30, 2025Advent Pharma Ltd. announced that they will report Q2, 2025 results on Jan 30, 2025
Reported Earnings • Nov 15Full year 2024 earnings released: EPS: ৳0.90 (vs ৳1.06 in FY 2023)Full year 2024 results: EPS: ৳0.90 (down from ৳1.06 in FY 2023). Revenue: ৳571.7m (up 2.4% from FY 2023). Net income: ৳84.0m (down 15% from FY 2023). Profit margin: 15% (down from 18% in FY 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 9% per year whereas the company’s share price has fallen by 13% per year.
Upcoming Dividend • Nov 14Upcoming dividend of ৳0.10 per shareEligible shareholders must have bought the stock before 21 November 2024. Payment date: 22 December 2024. Payout ratio is a comfortable 20% but the company is paying out more than the cash it is generating. Trailing yield: 1.2%. Lower than top quartile of Bangladeshi dividend payers (4.5%). Lower than average of industry peers (3.6%).
공시 • Nov 11Advent Pharma Ltd. to Report Q1, 2025 Results on Nov 13, 2024Advent Pharma Ltd. announced that they will report Q1, 2025 results on Nov 13, 2024
New Risk • Nov 06New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. Cash payout ratio: 138% Dividend yield: 1.1% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 12% per year over the past 5 years. Minor Risks Dividend is not well covered by cash flows (138% cash payout ratio). Revenue is less than US$5m (৳569m revenue, or US$4.7m). Market cap is less than US$100m (৳1.65b market cap, or US$13.8m).
Declared Dividend • Oct 31Dividend of ৳0.10 announcedShareholders will receive a dividend of ৳0.10. Ex-date: 21st November 2024 Payment date: 22nd December 2024 Dividend yield will be 0.6%, which is lower than the industry average of 2.5%. Sustainability & Growth Dividend is covered by earnings (20% earnings payout ratio) but not covered by cash flows (138% cash payout ratio). The dividend has increased by an average of 5.2% per year over the past 6 years and payments have been stable during that time. The company's earnings per share (EPS) would need to decline by 78% to shift the payout ratio to a potentially unsustainable range, which is more than the 12% EPS decline seen over the last 5 years.
공시 • Oct 30Advent Pharma Ltd., Annual General Meeting, Dec 29, 2024Advent Pharma Ltd., Annual General Meeting, Dec 29, 2024, at 12:00 Central Asia Standard Time.
Valuation Update With 7 Day Price Move • Oct 23Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ৳19.80, the stock trades at a trailing P/E ratio of 20x. Average trailing P/E is 19x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 31% over the past three years.
공시 • Oct 21Advent Pharma Ltd. to Report Fiscal Year 2024 Results on Oct 28, 2024Advent Pharma Ltd. announced that they will report fiscal year 2024 results on Oct 28, 2024
Valuation Update With 7 Day Price Move • Sep 26Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ৳19.90, the stock trades at a trailing P/E ratio of 20.1x. Average trailing P/E is 21x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 23% over the past three years.
Buy Or Sell Opportunity • Sep 26Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 23% to ৳19.90. The fair value is estimated to be ৳25.32, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.1% over the last 3 years. Earnings per share has declined by 5.5%.
공시 • Sep 03Advent Pharma Ltd. Appoints Md. Delwar Hossen as Company SecretaryAdvent Pharma Ltd. announced that as per the decision of the Board of Directors, Mr. Md. Delwar Hossen has been appointed as the Company Secretary of the company.
Buy Or Sell Opportunity • Jun 13Now 20% overvaluedOver the last 90 days, the stock has fallen 11% to ৳25.40. The fair value is estimated to be ৳21.14, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.1% over the last 3 years. Earnings per share has declined by 5.5%.
New Risk • May 10New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: ৳564m (US$4.8m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.2% average weekly change). Earnings have declined by 12% per year over the past 5 years. Minor Risks Revenue is less than US$5m (৳564m revenue, or US$4.8m). Market cap is less than US$100m (৳2.81b market cap, or US$24.0m).
Valuation Update With 7 Day Price Move • May 02Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ৳26.90, the stock trades at a trailing P/E ratio of 27.3x. Average trailing P/E is 26x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 48% over the past three years.
공시 • Apr 30Advent Pharma Ltd. to Report Q3, 2024 Results on Apr 29, 2024Advent Pharma Ltd. announced that they will report Q3, 2024 results on Apr 29, 2024
Reported Earnings • Feb 09Second quarter 2024 earnings released: EPS: ৳0.27 (vs ৳0.28 in 2Q 2023)Second quarter 2024 results: EPS: ৳0.27 (down from ৳0.28 in 2Q 2023). Revenue: ৳137.1m (up 4.1% from 2Q 2023). Net income: ৳25.1m (down 5.5% from 2Q 2023). Profit margin: 18% (down from 20% in 2Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Feb 05Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ৳28.60, the stock trades at a trailing P/E ratio of 28.6x. Average trailing P/E is 26x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 31% over the past three years.
공시 • Jan 24Advent Pharma Ltd. to Report Q2, 2023 Results on Jan 30, 2024Advent Pharma Ltd. announced that they will report Q2, 2023 results on Jan 30, 2024
New Risk • Jan 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Bangladeshi stocks, typically moving 5.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 11% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (5.6% average weekly change). Market cap is less than US$100m (৳2.29b market cap, or US$20.9m).
Valuation Update With 7 Day Price Move • Dec 10Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ৳27.00, the stock trades at a trailing P/E ratio of 25.5x. Average trailing P/E is 28x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 24% over the past three years.
Upcoming Dividend • Nov 14Upcoming dividend of ৳0.20 per share at 0.9% yieldEligible shareholders must have bought the stock before 21 November 2023. Payment date: 28 January 2024. Payout ratio is a comfortable 19% but the company is not cash flow positive. Trailing yield: 0.9%. Lower than top quartile of Bangladeshi dividend payers (3.3%). Lower than average of industry peers (2.5%).
공시 • Nov 13Advent Pharma Ltd. to Report Q1, 2024 Results on Nov 14, 2023Advent Pharma Ltd. announced that they will report Q1, 2024 results on Nov 14, 2023
공시 • Oct 31+ 1 more updateAdvent Pharma Ltd., Annual General Meeting, Dec 28, 2023Advent Pharma Ltd., Annual General Meeting, Dec 28, 2023, at 12:00 Bangladesh Standard Time.
공시 • Oct 20Advent Pharma Ltd. to Report Fiscal Year 2023 Results on Oct 28, 2023Advent Pharma Ltd. announced that they will report fiscal year 2023 results on Oct 28, 2023
Reported Earnings • May 18Third quarter 2023 earnings released: EPS: ৳0.28 (vs ৳0.29 in 3Q 2022)Third quarter 2023 results: EPS: ৳0.28 (down from ৳0.29 in 3Q 2022). Revenue: ৳149.4m (up 3.0% from 3Q 2022). Net income: ৳26.5m (down 3.4% from 3Q 2022). Profit margin: 18% (down from 19% in 3Q 2022). The decrease in margin was driven by higher expenses.
Reported Earnings • Feb 15Second quarter 2023 earnings released: EPS: ৳0.28 (vs ৳0.28 in 2Q 2022)Second quarter 2023 results: EPS: ৳0.28 (up from ৳0.28 in 2Q 2022). Revenue: ৳131.7m (up 4.4% from 2Q 2022). Net income: ৳26.6m (up 2.2% from 2Q 2022). Profit margin: 20% (in line with 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.
Valuation Update With 7 Day Price Move • Dec 21Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to ৳23.30, the stock trades at a trailing P/E ratio of 19.7x. Average trailing P/E is 28x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 21% over the past three years.
Valuation Update With 7 Day Price Move • Dec 04Investor sentiment improved over the past weekAfter last week's 19% share price gain to ৳28.40, the stock trades at a trailing P/E ratio of 24x. Average trailing P/E is 24x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 41% over the past three years.
Reported Earnings • Nov 27Third quarter 2022 earnings released: EPS: ৳0.29 (vs ৳0.22 in 3Q 2021)Third quarter 2022 results: EPS: ৳0.29 (up from ৳0.22 in 3Q 2021). Revenue: ৳145.1m (up 15% from 3Q 2021). Net income: ৳27.5m (up 32% from 3Q 2021). Profit margin: 19% (up from 17% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.
Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 8 experienced directors. No highly experienced directors. 2 independent directors (7 non-independent directors). Independent Director Sheikh Karimuzzaman was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공시 • Nov 01Advent Pharma Ltd. Recommends Cash Dividend for the Year Ended June 30, 2022The Board of Directors of Advent Pharma Ltd. has recommended 2% cash dividend only for general shareholders (Excluding Sponsors and Directors) for the year ended June 30, 2022.
Valuation Update With 7 Day Price Move • Oct 19Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to ৳24.50, the stock trades at a trailing P/E ratio of 20.7x. Average trailing P/E is 24x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 26% over the past three years.
Valuation Update With 7 Day Price Move • Aug 31Investor sentiment improved over the past weekAfter last week's 19% share price gain to ৳28.40, the stock trades at a trailing P/E ratio of 24x. Average trailing P/E is 25x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 11% over the past three years.
Reported Earnings • May 29Third quarter 2022 earnings released: EPS: ৳0.29 (vs ৳0.22 in 3Q 2021)Third quarter 2022 results: EPS: ৳0.29 (up from ৳0.22 in 3Q 2021). Revenue: ৳145.1m (up 15% from 3Q 2021). Net income: ৳27.5m (up 32% from 3Q 2021). Profit margin: 19% (up from 17% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has remained flat, which means it is well ahead of earnings.
Board Change • Apr 27Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 8 experienced directors. No highly experienced directors. 2 independent directors (7 non-independent directors). Independent Director Sheikh Karimuzzaman was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Mar 14Investor sentiment improved over the past weekAfter last week's 15% share price gain to ৳28.60, the stock trades at a trailing P/E ratio of 25.7x. Average trailing P/E is 26x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 9.3% over the past three years.
Upcoming Dividend • Nov 14Upcoming dividend of ৳0.20 per shareEligible shareholders must have bought the stock before 21 November 2021. Payment date: 16 January 2022. Trailing yield: 0.8%. Lower than top quartile of Bangladeshi dividend payers (3.0%). Lower than average of industry peers (1.7%).
Valuation Update With 7 Day Price Move • Oct 20Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ৳28.80, the stock trades at a trailing P/E ratio of 27.8x. Average trailing P/E is 28x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 3.2% over the past three years.
Valuation Update With 7 Day Price Move • Oct 05Investor sentiment improved over the past weekAfter last week's 23% share price gain to ৳32.20, the stock trades at a trailing P/E ratio of 31.1x. Average trailing P/E is 29x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 31% over the past three years.
Reported Earnings • Sep 10Third quarter 2021 earnings released: EPS ৳0.23 (vs ৳0.23 in 3Q 2020)The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2021 results: Revenue: ৳125.2m (down 14% from 3Q 2020). Net income: ৳20.8m (up 1.4% from 3Q 2020). Profit margin: 17% (up from 14% in 3Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Jun 08Investor sentiment improved over the past weekAfter last week's 20% share price gain to ৳26.30, the stock trades at a trailing P/E ratio of 25.5x. Average trailing P/E is 22x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 2.9% over the past three years.
Valuation Update With 7 Day Price Move • May 17Investor sentiment improved over the past weekAfter last week's 16% share price gain to ৳23.10, the stock trades at a trailing P/E ratio of 22.4x. Average trailing P/E is 20x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 23% over the past three years.
Is New 90 Day High Low • Jan 07New 90-day high: ৳23.70The company is up 14% from its price of ৳20.73 on 08 October 2020. The Bangladeshi market is up 13% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 20% over the same period.
Reported Earnings • Dec 24Third quarter 2020 earnings released: EPS ৳0.23The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2020 results: Revenue: ৳144.8m (down 9.2% from 3Q 2019). Net income: ৳20.5m (down 54% from 3Q 2019). Profit margin: 14% (down from 28% in 3Q 2019). The decrease in margin was primarily driven by lower revenue.
공시 • Jul 07Advent Pharma Ltd. to Report Q3, 2020 Results on Jun 24, 2020Advent Pharma Ltd. announced that they will report Q3, 2020 results on Jun 24, 2020
